A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. Raymond James cut shares of ANI Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and raised their price target for the stock from $73.00 to $82.00 in a report on Friday, May 10th. Canaccord Genuity restated a “buy” rating and issued a $90.00 price target (up from $80.00) on shares of ANI Pharmaceuticals in a report on Monday, May 13th. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $89.00 price target on shares of ANI Pharmaceuticals in a report on Thursday, May 9th. Two analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $89.00.
NASDAQ:ANIP opened at $72.62 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 0.92 and a quick ratio of 0.67. The firm has a market capitalization of $994.28 million, a PE ratio of 17.64 and a beta of 2.17. The business has a fifty day moving average of $81.42. ANI Pharmaceuticals has a 12 month low of $36.92 and a 12 month high of $86.96.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.16. The business had revenue of $54.36 million during the quarter, compared to analysts’ expectations of $55.20 million. ANI Pharmaceuticals had a net margin of 6.58% and a return on equity of 28.63%. The business’s quarterly revenue was up 15.0% on a year-over-year basis. During the same period last year, the company posted $1.13 earnings per share. On average, research analysts forecast that ANI Pharmaceuticals will post 5.57 EPS for the current year.
In other news, SVP Robert W. Schrepfer sold 2,409 shares of ANI Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $71.13, for a total transaction of $171,352.17. Following the completion of the transaction, the senior vice president now directly owns 55,927 shares in the company, valued at $3,978,087.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas Haughey acquired 2,500 shares of ANI Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The shares were acquired at an average price of $69.30 per share, with a total value of $173,250.00. Following the completion of the acquisition, the director now directly owns 6,291 shares of the company’s stock, valued at $435,966.30. The disclosure for this purchase can be found here. Insiders sold 50,911 shares of company stock valued at $3,585,114 over the last 90 days. Corporate insiders own 24.70% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its holdings in shares of ANI Pharmaceuticals by 1.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 518,427 shares of the specialty pharmaceutical company’s stock valued at $23,339,000 after buying an additional 6,546 shares during the last quarter. Investment Counselors of Maryland LLC grew its holdings in shares of ANI Pharmaceuticals by 1.1% during the second quarter. Investment Counselors of Maryland LLC now owns 279,979 shares of the specialty pharmaceutical company’s stock valued at $23,014,000 after buying an additional 3,100 shares during the last quarter. First Manhattan Co. grew its holdings in shares of ANI Pharmaceuticals by 2.2% during the first quarter. First Manhattan Co. now owns 240,166 shares of the specialty pharmaceutical company’s stock valued at $16,941,000 after buying an additional 5,171 shares during the last quarter. Global Alpha Capital Management Ltd. grew its holdings in shares of ANI Pharmaceuticals by 47.6% during the second quarter. Global Alpha Capital Management Ltd. now owns 142,446 shares of the specialty pharmaceutical company’s stock valued at $11,709,000 after buying an additional 45,935 shares during the last quarter. Finally, Phocas Financial Corp. grew its holdings in shares of ANI Pharmaceuticals by 8.9% during the first quarter. Phocas Financial Corp. now owns 140,977 shares of the specialty pharmaceutical company’s stock valued at $9,945,000 after buying an additional 11,501 shares during the last quarter. Hedge funds and other institutional investors own 63.65% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Further Reading: Market Capitalization – What it Means for Investors
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.